Healthcare, Pharma & Life Sciences

Astellas Doses First Patient in Phase 3 Lung Cancer Trial of Setidegrasib

Image
Astellas Doses First Patient in Phase 3 Lung Cancer Trial of Setidegrasib

Tokyo – September 24, 2026 -- Astellas Pharma Inc. (TSE: 4503) has dosed the first patient in a Phase 3 study evaluating setidegrasib, an investigational KRAS G12D-targeted protein degrader, against docetaxel in previously treated non-small cell lung cancer (NSCLC) patients carrying the KRAS G12D mutation.

Trial targets patients who progressed on chemotherapy and checkpoint inhibitors

The randomized, open-label study will enroll approximately 356 patients across multiple countries whose locally advanced or metastatic NSCLC has progressed after platinum-based chemotherapy and checkpoint inhibitor therapy. Dual primary endpoints are progression-free survival, assessed by blinded independent central review, and overall survival.

Bladder Cancer Treatment Market to Hit $11.33B by 2034

Image
Bladder Cancer Treatment Market to Hit $11.33B by 2034

Pune, India – September 24, 2026 -- The global bladder cancer treatment market was valued at $5.13 billion in 2025 and is projected to reach $11.33 billion by 2034, expanding at a 9.2% compound annual growth rate, according to a new analysis from Maximize Market Research.

Immunotherapy and antibody-drug conjugates drive treatment shift

Adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors is accelerating across non-muscle-invasive and muscle-invasive bladder cancer segments. Pharmaceutical companies are directing R&D spend toward intravesical drug delivery, gene therapy, and biomarker-driven precision oncology to improve outcomes for recurrent and metastatic urothelial cancer patients.

Viking Therapeutics Launches $400M Dual Offering to Fund Obesity Drug Pipeline

Image
Viking Therapeutics Launches $400M Dual Offering to Fund Obesity Drug Pipeline

San Diego – September 24, 2026 -- Viking Therapeutics plans to raise $400 million through simultaneous public offerings of $200 million in common stock and $200 million in convertible senior notes due 2032, with proceeds earmarked for its obesity drug pipeline.

Viking structures two independent capital raises with built-in flexibility

The biopharmaceutical company intends to grant underwriters a 30-day option to purchase an additional $30 million in common stock and a separate 30-day option for up to $30 million more in notes to cover over-allotments. Completion of one offering is not contingent on the other, giving Viking flexibility if market conditions shift. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are serving as joint book-running managers for both transactions.

ULC Franchise Tops 300 Territories, Launches 50-Site Australia Expansion

Image
ULC Franchise Tops 300 Territories, Launches 50-Site Australia Expansion

Newport Beach – September 24, 2026 -- Ultimate Longevity Center (ULC) has surpassed 300 sold territories worldwide after unveiling a 50-location Australian franchise rollout, with the first center confirmed for Sydney's Double Bay in Q1 2027.

ULC crosses 300 global territories within a year of launching U.S. franchise sales

The longevity and human-optimization brand, built by Sequel Brands founder Anthony Geisler alongside human biologist Gary Brecka and precision health platform Lifeforce, has sold more than 275 territories across the United States since opening franchise sales in 2026, including 200 in its first four months. The newly announced 50-center Australian network pushes the brand's global footprint past 300 territories.

AmeriHealth Caritas Expands HealthSherpa Deal to Billing, Reconciliation

Sacramento, Calif. – September 24, 2026 -- HealthSherpa is expanding its multi-year partnership with AmeriHealth Caritas to include Marketplace Operations, its enrollment, premium billing and reconciliation platform for individual and family health plans sold on and off the Health Insurance Marketplace.

AmeriHealth Caritas will use the platform to reconcile enrollments and collect premiums

Under the expanded deal, AmeriHealth Caritas will process and reconcile enrollments directly with the Health Insurance Marketplace, collect subsidy and member premiums, and resolve data discrepancies before they affect member bills or coverage status.

BPD Health Rebrands, Positions Itself as Healthcare Growth Partner

Image
BPD Health Rebrands, Positions Itself as Healthcare Growth Partner

Boca Raton, Fla. – September 24, 2026 -- BPD Health has launched a new brand identity, "It's Good to Grow," repositioning the two-decade-old healthcare marketing firm as a strategic growth partner for hospitals, life sciences firms and health innovators.

BPD traces its evolution from an advertising agency to a growth strategy firm

The company has operated under three names over more than 20 years: BPD Advertising, BPD Healthcare, and now BPD Health. Each iteration marked an expansion of scope, moving from healthcare marketing services toward broader strategic growth advisory work for health systems, life sciences companies, healthcare associations and consumer health brands.

Horizon Advances 69-Bed Recovery Center After $25.5M State Grant Approval

Image
Horizon Advances 69-Bed Recovery Center After $25.5M State Grant Approval

Burlingame – September 24, 2026 -- Horizon Treatment Services will proceed with a 69-bed Recovery Center at 826 Mahler Road in Burlingame after the California Department of Health Care Services approved relocating the project's state funding and the San Mateo County Board of Supervisors approved a $2.5 million local match.

State grant of $25.5 million anchors integrated treatment facility

The project is backed by a $25.5 million grant from California's Behavioral Health Continuum Infrastructure Program (BHCIP). The facility will consolidate sobering, withdrawal management, and residential treatment services into a single site, expanding medically supervised substance use disorder care for San Mateo County residents.

AlloSource Honors Three Surgeons With Gitelis Inspiration Award

Image
AlloSource Honors Three Surgeons With Gitelis Inspiration Award

Centennial, Colo. – September 24, 2026 -- AlloSource has named three physicians recipients of its 2026 Dr. Steven Gitelis Inspiration Award, recognizing clinical use of donated human tissue in reconstructive, burn and orthopedic care.

Three physicians recognized for advancing tissue-based medicine

Dr. Victor Stams, a plastic surgeon at Carle Foundation Hospital in Champaign, Illinois, was cited for reconstructive surgery leadership using AlloSource's AlloMend® tissue product. Dr. Sigrid Blome-Eberwein, Associate Director of the Regional Burn Center at Lehigh Valley Hospital Network in Allentown, Pennsylvania, was recognized for treating severe burns with split-thickness skin allografts. Dr. Robert Meislin, a hip specialist at NYU Langone Health, was honored for using AlloSource's pre-sutured fascia product, AceConnex®, in orthopedic mobility restoration.

Academy of Nutrition and Dietetics Launches Medical School Nutrition Initiative

Image
Academy of Nutrition and Dietetics Launches Medical School Nutrition Initiative

Chicago – September 24, 2026 -- The Academy of Nutrition and Dietetics, working with the Accreditation Council for Education in Nutrition and Dietetics (ACEND), has launched an initiative to embed evidence-based nutrition training into U.S. medical school curricula, citing rising attention from the U.S. Department of Health and Human Services (HHS) as a catalyst for the effort.

Academy rolls out a microcredential framework to standardize nutrition training

The ACEND Nutrition in Medical Education Microcredential Framework allows accredited nutrition and dietetics programs to convert existing coursework into microlearning units aligned with ACEND curriculum competencies and the HHS Medical Education Nutrition Competency Framework. The tool is designed to give medical schools a structured, program-level path to add nutrition content without building curricula from scratch.

WovenX Health Wins 1871 Industry Disrupter Award for GI Access Model

Chicago – September 24, 2026 -- WovenX Health, a Chicago-based specialty care platform, has won the Industry Disrupter Award at 1871's 19th Annual Momentum Awards for its model expanding access to gastroenterology care.

National GI wait times average 40 days as two-thirds of U.S. counties lack a specialist

One in five Americans is affected by a gastrointestinal condition, yet the average wait for a GI consult has grown to 40 days nationally, according to the company. GI-related visits account for 10% of all emergency department visits, 86% of which WovenX says are avoidable with timely specialty access.